Assessment of tumor biomarkers based on a Turkish city hospital’s data

Biomarkers can be objectively measured and evaluate the processes of normal biological pathogenic, and pharmacological answers to medications. This study aimed to evaluate the Cancer antigen 15-3 (CA 15-3); Cancer antigen 19-9 (CA 19-9); Cancer antigen 72-4 (CA 72-4); Cancer antigen 125 (CA 125); Carcinoembryonic antigen (CEA); Neuron-specific enolase (NSE), and their test requests in Ankara Bilkent City Hospital. All the results recorded between 01/01/2022 and 31/12/2022 were acquired from our hospital laboratory information system.136,043 tests, consisting of 28,132 CA 15-3, 37,543 CA 19-9, 3135 CA 72-4, 29,996 CA125, 36,788 CEA, and 449 NSE tests, were enrolled. The frequency of positive tumor markers were as follows: CA 15-3 U/mL (N=996, 3.5%), CA 19-9 U/mL (N=4716,12.6%), CA 72-4 U/mL (N=174, 5.6 %), CA125 U/mL (N=3488, 11.6%), CEA ng/mL (N=1699, 4.6%), NSE IU/ mL (N=396, 88.2%). Statistical differences in CA 15-3 U/mL(p<0.001), CA 19-9 U/mL (p=0.016), CA125 U/mL(p<0.001), CEA ng/mLp<0.001), and NSE IU/ Ml (p<.001) tests among genders, and statistical differences in CA 15-3(p<0.001), CA19-9 (p<0.001), CA 72-4 (p=0.038), CA125(p<0.001), CEA(p<0.001), NSE(p<0.01) among age intervals were observed. Our findings may indicate that; tumor biomarker tests may be requested with a low specific diagnosis purpose. Inappropriate testing orders for tumor biomarkers may increase the risk of false above-reference results. patient may experience fear and anxiety, hospital costs may increase. Clinicians should consider all these circumstances before requesting tumor biomarker tests.